These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20665660)

  • 21. Cytoskeleton Aberrations in Alkaptonuric Chondrocytes.
    Geminiani M; Gambassi S; Millucci L; Lupetti P; Collodel G; Mazzi L; Frediani B; Braconi D; Marzocchi B; Laschi M; Bernardini G; Santucci A
    J Cell Physiol; 2017 Jul; 232(7):1728-1738. PubMed ID: 27454006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.
    Preston AJ; Keenan CM; Sutherland H; Wilson PJ; Wlodarski B; Taylor AM; Williams DP; Ranganath LR; Gallagher JA; Jarvis JC
    Ann Rheum Dis; 2014 Jan; 73(1):284-9. PubMed ID: 23511227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pigmentation Chemistry and Radical-Based Collagen Degradation in Alkaptonuria and Osteoarthritic Cartilage.
    Chow WY; Norman BP; Roberts NB; Ranganath LR; Teutloff C; Bittl R; Duer MJ; Gallagher JA; Oschkinat H
    Angew Chem Int Ed Engl; 2020 Jul; 59(29):11937-11942. PubMed ID: 32219972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of an in vitro model to investigate joint ochronosis in alkaptonuria.
    Tinti L; Taylor AM; Santucci A; Wlodarski B; Wilson PJ; Jarvis JC; Fraser WD; Davidson JS; Ranganath LR; Gallagher JA
    Rheumatology (Oxford); 2011 Feb; 50(2):271-7. PubMed ID: 20952450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antioxidants inhibit SAA formation and pro-inflammatory cytokine release in a human cell model of alkaptonuria.
    Spreafico A; Millucci L; Ghezzi L; Geminiani M; Braconi D; Amato L; Chellini F; Frediani B; Moretti E; Collodel G; Bernardini G; Santucci A
    Rheumatology (Oxford); 2013 Sep; 52(9):1667-73. PubMed ID: 23704321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alkaptonuria: a very rare metabolic disorder.
    Aquaron R
    Indian J Biochem Biophys; 2013 Oct; 50(5):339-44. PubMed ID: 24772955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urine homogentisic acid and tyrosine: simultaneous analysis by liquid chromatography tandem mass spectrometry.
    Hughes AT; Milan AM; Christensen P; Ross G; Davison AS; Gallagher JA; Dutton JJ; Ranganath LR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 963():106-12. PubMed ID: 24952314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural history of alkaptonuria revisited: analyses based on scoring systems.
    Ranganath LR; Cox TF
    J Inherit Metab Dis; 2011 Dec; 34(6):1141-51. PubMed ID: 21748407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Homogentisic acid and structurally related compounds as intermediates in plasma soluble melanin formation and in tissue toxicities.
    Hegedus ZL; Nayak U
    Arch Int Physiol Biochim Biophys; 1994; 102(3):175-81. PubMed ID: 8000039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuria.
    Hughes JH; Liu K; Plagge A; Wilson PJM; Sutherland H; Norman BP; Hughes AT; Keenan CM; Milan AM; Sakai T; Ranganath LR; Gallagher JA; Bou-Gharios G
    Hum Mol Genet; 2019 Dec; 28(23):3928-3939. PubMed ID: 31600782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Raman Spectroscopy identifies differences in ochronotic and non-ochronotic cartilage; a potential novel technique for monitoring ochronosis.
    Taylor AM; Jenks DD; Kammath VD; Norman BP; Dillon JP; Gallagher JA; Ranganath LR; Kerns JG
    Osteoarthritis Cartilage; 2019 Aug; 27(8):1244-1251. PubMed ID: 31022456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferences of homogentisic acid (HGA) on routine clinical chemistry assays in serum and urine and the implications for biochemical monitoring of patients with alkaptonuria.
    Curtis SL; Roberts NB; Ranganath LR
    Clin Biochem; 2014 May; 47(7-8):640-7. PubMed ID: 24373924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Malondialdehyde oxidation of cartilage collagen by chondrocytes.
    Tiku ML; Allison GT; Naik K; Karry SK
    Osteoarthritis Cartilage; 2003 Mar; 11(3):159-66. PubMed ID: 12623287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms involved in the unbalanced redox homeostasis in osteoblastic cellular model of Alkaptonuria.
    Schiavone ML; Pecorelli A; Woodby B; Ferrara F; Pambianchi E; Santucci A; Valacchi G
    Arch Biochem Biophys; 2020 Sep; 690():108416. PubMed ID: 32502471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exacerbation of the ochronosis of alkaptonuria due to renal insufficiency and improvement after renal transplantation.
    Introne WJ; Phornphutkul C; Bernardini I; McLaughlin K; Fitzpatrick D; Gahl WA
    Mol Genet Metab; 2002; 77(1-2):136-42. PubMed ID: 12359141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urinary homogentisic acid in alkaptonuric and healthy children.
    Oláh AV; Llyés I; Szoke A; Csízy I; Tóth J; Varga J
    Clin Chem Lab Med; 2003 Mar; 41(3):356-9. PubMed ID: 12705346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experimental studies on the pathogenesis of ochronotic arthropathy. The effects of homogentisic acid on adult and fetal articular chondrocyte morphology, proliferative capacity and synthesis of proteoglycans in vitro.
    Kirkpatrick CJ; Mohr W; Mutschler W
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1984; 47(4):347-60. PubMed ID: 6151314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osteoarticular cells tolerate short-term exposure to nitisinone-implications in alkaptonuria.
    Mistry JB; Jackson DJ; Bukhari M; Taylor AM
    Clin Rheumatol; 2016 Feb; 35(2):513-6. PubMed ID: 26024586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment.
    Ranganath LR; Milan AM; Hughes AT; Dutton JJ; Fitzgerald R; Briggs MC; Bygott H; Psarelli EE; Cox TF; Gallagher JA; Jarvis JC; van Kan C; Hall AK; Laan D; Olsson B; Szamosi J; Rudebeck M; Kullenberg T; Cronlund A; Svensson L; Junestrand C; Ayoob H; Timmis OG; Sireau N; Le Quan Sang KH; Genovese F; Braconi D; Santucci A; Nemethova M; Zatkova A; McCaffrey J; Christensen P; Ross G; Imrich R; Rovensky J
    Ann Rheum Dis; 2016 Feb; 75(2):362-7. PubMed ID: 25475116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.
    Ranganath LR; Khedr M; Milan AM; Davison AS; Hughes AT; Usher JL; Taylor S; Loftus N; Daroszewska A; West E; Jones A; Briggs M; Fisher M; McCormick M; Judd S; Vinjamuri S; Griffin R; Psarelli EE; Cox TF; Sireau N; Dillon JP; Devine JM; Hughes G; Harrold J; Barton GJ; Jarvis JC; Gallagher JA
    Mol Genet Metab; 2018 Sep; 125(1-2):127-134. PubMed ID: 30055994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.